10-K · March 30, 2026
Avenue Therapeutics is a clinical-stage specialty pharma company with no approved products and a pipeline focused on IV tramadol (post-op analgesia) and ATX-04 (clenbuterol for Pompe disease). The company sold its…
Earnings analysis · 10-Q
ATXI earnings analysis
Filed May 8, 2026 · Our reading of the company's report
The latest report
Avenue Therapeutics continues to operate at a net loss, reporting a loss of $695,000 for Q1 2026, significantly improved from a loss of $1.9 million in the prior year. Total cash reserves decreased to $2.4 million, down…
Read full summary
Avenue Therapeutics continues to operate at a net loss, reporting a loss of $695,000 for Q1 2026, significantly improved from a loss of $1.9 million in the prior year. Total cash reserves decreased to $2.4 million, down from $2.9 million as of year-end 2025, raising concerns about liquidity. Importantly, R&D expenses decreased, reflecting a company-wide effort to manage costs amid ongoing development of key product candidates, particularly ATX-04 and IV tramadol.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.21
What stood out
-
Improved Net Loss Compared to Previous Year
Net loss for Q1 2026 was $695,000, a 63% improvement from $1.86 million in Q1 2025.
-
Decrease in Operating Expenses
Total operating expenses decreased to $1.9 million in Q1 2026 from $3.1 million in Q1 2025, marking a 63% reduction.
-
Cash Position Remains Low
As of March 31, 2026, cash and cash equivalents stood at $2.4 million, down from $2.9 million at December 31, 2025.
-
Major Contracts for Future Revenue Potential
Executed a license agreement with Duke University for ATX-04, which includes potential milestone payments totaling approximately $15.6 million.
-
R&D Cost Management
R&D expenses reduced to $200,000 in Q1 2026 from $400,000 in Q1 2025, highlighting effective cost controls.
-
Optimistic Discussions with FDA
Management is preparing for a pivotal IND meeting with the FDA regarding ATX-04, aiming to align on study design.
What to watch
-
Substantial Doubt About Going Concern
The 10-Q states substantial doubt about the company's ability to continue as a going concern within 12 months.
-
Dependence on Funding for Operations
Continued operations rely heavily on future financing, raising risks if new capital cannot be secured.
-
No Revenue Generated Yet
Avenue remains a pre-revenue stage company, posing a risk if product approval timelines are delayed.
Management's outlook
Management did not provide specific revenue or EPS guidance in the 10-Q.
Earlier filings 4
10-Q · August 9, 2024
Avenue Therapeutics reported no revenue for Q2 and a net loss of $2.70M for the quarter ($7.05M year-to-date). Operating loss narrowed to $2.823M in Q2 from $3.923M in Q2 2023, and cash increased to $4.919M at June 30,…
10-Q · May 15, 2024
Avenue Therapeutics reported no revenue and a net loss of $4.3M for Q1 2024 (versus $7.6M loss in Q1 2023), with loss per share improving to $(15.40) from $(101.57) as weighted average shares rose to 562,031 from…
10-Q · August 11, 2023
Avenue Therapeutics reported no product revenue and a widening loss in Q2 2023, recording a net loss of $4,016 thousand for the three months ended June 30, 2023 (vs. $604 thousand in Q2 2022) and net loss per share of…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.